Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy  by Meijnders, P. et al.
ejc supplements 10, no. 1 (2012) 105–111
Clinical achievements of the EORTC Lymphoma Group and
aspects of future group strategy
P. Meijndersa,*, P. Cardeb, T. Girinskyc, J.C. Kluin-Nelemansd, M. Henry-Amare,
J.M.M. Raemaekers f , M. Karraschg, R. van der Maazenh, for the EORTC Lymphoma Group
a Department of Radiotherapy, ZNA Middelheim, University of Antwerp, Antwerp, Belgium
bDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif, France
c Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
d Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
e Centre de Traitement des Donne´es du Cance´ropoˆle Nord-Ouest, Centre Franc¸ois Baclesse, Caen, France
f Department of Hematology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
g European Organization for Research and Treatment of Cancer, Brussels, Belgium
hDepartment of Radiotherapy, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
article info
Keywords:
EORTC Lymphoma Group
Hodgkin lymphoma
Late toxicity
Involved node radiotherapy
Prognostic factors
abstract
Since1964, the EORTC Lymphoma Group has conducted nine consecutive randomized
phase III trials on early-stage Hodgkin lymphoma aimed at increasing efﬁcacy
while decreasing short- and long-term toxicities. Event-free and overall survival
signiﬁcantly improved from about 50% and 70%, respectively, in the early years to
over 80% and 90%, respectively, more recently. Identiﬁcation of prognostic subgroups
appeared to be a successful method to tailor treatment strategies. Radiotherapy ﬁelds
have become more restricted whereas chemotherapy has become standard. Early
PET-CT has been introduced to investigate the possibility of treatment adaptation.
Longitudinal quality-of-life assessment has become an integral part of our studies.
An ongoing study focuses on the rehabilitation and quality of long-term survival
in all 6658 Hodgkin lymphoma patients treated in EORTC trials since the earliest
beginning. In advanced stages overall outcome has improved as well with 10-year
survival rates of over 75%.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction
The aim of the EORTC Lymphoma Group (LG) is to
develop optimal treatment strategies for malignant
lymphomas and further to study their natural his-
tory, diagnosis, treatment and sequelae of treatment.
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Until 2006 Hodgkin Lymphoma (HL) as well as Non-
Hodgkin Lymphoma (NHL) studies were performed by
the group. 1 Due to strong competition of several
national NHL groups, it became increasingly difﬁcult to
successfully complete NHL clinical trials. Therefore the
group changed its strategy and decided to focus mainly
on HL for the next years. Successful cooperation has been
established with the French Groupe d’E´tude des Lymphomes
de l’Adulte (GELA) and recently with the Italian Fondazione
Italiana Linfomi (FIL), and there is an active exchange with
the German Hodgkin Study Group (GHSG).
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2. Achievements of the EORTC Lymphoma Group
2.1. Identiﬁcation and use of pre-registered initial tumor and
patient characteristics as key parameters for adaptation of
treatment strategy in localized Hodgkin Lymphoma: 50 years
of continuous progress
In the early 1960’s, most studies were conducted by
Anglo-American academic cooperative groups which
were not used to sharing clinical research with the
European continent. After Easson had claimed that HL
could be cured, 2 clinical research leaders from Belgium,
France, Italy, The Netherlands and Sweden decided in
1964 to join forces in the “Radiotherapy-Chemotherapy
Cooperative Group” (now Lymphoma Group) and con-
duct innovative clinical trials. 1 Beside improvement
in patient recruitment, the gathering induced close
day-to-day work of medical oncologists/hematologists,
surgeons, radiation oncologists and pathologists as well
as biostatisticians and data managers, a determined
attitude that made the EORTC successful. The LG has
continuously performed trials over the last ﬁve decades
to improve the treatment outcome for HL patients. In the
period from 1964 to 1988, trials (H1−H6) were aimed at
improving immediate results. Among other beneﬁts due
to the LG are the deletion of staging laparotomy (H6F
trial) as a diagnostic/prognostic procedure and of total
nodal irradiation as a standard treatment (H5U). Because
of the greatly improved treatment results, later trials
were mainly aimed at reducing (late) treatment toxicity
while maintaining excellent disease control (H7−H10 for
early-stage disease and H34 and the upcoming H11 for
advanced disease). 3−5
The objectives of the ﬁrst two trials were to improve
treatment efﬁcacy. Efforts were made to identify clinical
and biological parameters, easy to assess and collect
and highly reproducible, that could be used to adapt
treatment strategy. Two propagation models of the tumor
(the relation of tumor mass to lymphatic spreading and
to hematogenous dissemination) and its particular host–
tumor relationship were built. The parameters identiﬁed
were ﬁrst used to delineate subgroups for which the risk
of progression or relapse could be predicted. Actually,
the second trial already split patients into two groups
of favorable and unfavorable prognosis. Patients being
followed up on a regular basis until death, their fate after
speciﬁc treatments was used to develop strategies to
maximize the yield of long-term responses andminimize
early and long-term toxicities. These results helped
to improve the understanding of other aspects of the
management of HL that were relevant for other tumors:
the biology of the disease, 6 the response to treatment
and its signiﬁcance, the risk for relapse, the risk for long-
term toxicities (secondary malignancies, cardiovascular,
pulmonary, digestive and fertility toxicities), 7−11 the
quality-of-life considering personal and socio-economic
aspects, the improvement in diagnostic procedures and
treatment techniques, 12 and in quality assurance and the
emergence of decision analysis models.
A major step was attained with the publication of
a general stratiﬁcation algorithm based on just six
parameters: age, sex, number of lymph node areas
involved, mediastinal bulk, B symptoms, and erythrocyte
sedimentation rate. 13 A scoring system was developed
and used to identify three prognostic subgroups called
very favorable, favorable, and unfavorable. This scoring
system was ﬁrst applied to the H7 trial in which
the validity of the deﬁnition of the three subgroups
was tested, patients belonging to the favorable (F) and
unfavorable (U) subgroups being randomized between
the appropriate reference treatment and a common
experimental treatment. 14 The results demonstrated
the usefulness of the scoring system, and it was
then applied to subsequent trials. It has also been
widely adopted (sometimes with adaptation) for early-
stage HL all over Europe and throughout the USA and
Canada. In the H8 trial this scoring system was used to
differentiate treatment. Involved ﬁeld radiotherapy (IFRT)
was compared to subtotal nodal radiotherapy (STNI)
either alone (in F subgroup) or in combination (in
U subgroup) with chemotherapy (MOPP-ABV). The results
in both arms were in favor of chemotherapy plus IFRT. 15
Figures 1 and 2 summarize the continuous improve-
ment achieved along the seven trials on early-stage HL
for which results are available. It shows that even with
limited treatment in low-risk patients, there is room for
improvement in treatment efﬁcacy while limiting the risk
of long-term treatment related toxicity.
With the availability of new imaging techniques
worldwide, the LG has recently completed a large
intergroup (GELA, FIL) randomized trial (H10, 2006–
2011, 1952 patients) with the objective of testing the
concept of early treatment adaptation by assessing
clinical response on PET-scan examination after two
Fig. 1 – Accrual in EORTC Lymphoma Group trials on
Hodgkin’s Lymphoma clinical stages I and II. H1: 1964–
1971; H2: 1972–1976; H5: 1977–1982; H6: 1982–1988;
H7: 1988–1993; H8: 1993–1998; H9: 1998–2004.
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Fig. 2 – (a) Overall cumulative event-free survival by trial
(1964–2004; 5,719 patients); (b) Overall survival by trial
(1964–2004; 5,719 patients).
cycles of chemotherapy. Also the localization of radiation
therapy should be established in the management of
patients with early-stage disease as well as the number
of chemotherapy cycles needed to induce a stable
clinical response. In order to achieve a consensus on
the interpretation of early PET scans an internet-based
network was built allowing experts to centrally review
all scans prospectively. 16 This cooperation gave support
for the formation of the EORTC Imaging Group.
In conclusion, the sustained effort that the EORTC-LG
placed on rigorous step-by-step analysis resulted in con-
siderable conceptual progress being made in improving
survival as well as in avoiding late toxicity.
2.2. Evolution of the LG radiotherapy concepts: from standard
to personalized radiation volumes, from lymph node regions
to individual involved lymph nodes
When Thomas Hodgkin ﬁrst described the disease
in 1832, it was incurable. After the introduction of
local radiotherapy using orthovoltage radiation, the ﬁrst
responses were seen and a small number of patients
were cured. Increased knowledge about the spread of the
disease and the development of techniques to irradiate
larger areas made it possible to cure patients with HL
already in the 1960’s. 17 Simultaneously, chemotherapy
was also developed and multiple combinations of
radiotherapy and chemotherapy have been studied ever
since.
The concept of delivering radiotherapy to lymph node
areas began in 1972. Irradiation to large lymph node
areas (either total nodal irradiation, TNI or STNI)
was used for over a quarter of a century, from
1972 (H2 trial) through 1998 (H8 trial). 5 In the H9
trial (1998–2004) smaller nodal areas were exclusively
irradiated (IFRT). All these radiation ﬁelds were based
on the Ann Arbor staging of nodal areas. Following
the introduction of chemotherapy regimens sufﬁciently
efﬁcient for eradicating microscopic disease and the
observation that local recurrences in patients treated
with chemotherapy alone were mainly occurring in
initially involved lymph nodes, 18 the LG Radiotherapy
Subcommittee in 2001 developed the concept of involved
node radiotherapy (INRT) for patients with early-stage
HL, which was implemented in 2006 in the H10 trial. 19
In addition, the growing evidence of late effects following
radiotherapy (dose- and volume-related) also contributed
to the reduction of radiation ﬁeld and dose as much as
possible. 4,20,21
The INRT concept contends that radiotherapy should
only be delivered to involved lymph nodes and should
encompass the initial lymph node volumes, modiﬁed,
however, to ﬁt to post-chemotherapy anatomic bound-
aries often different from the anatomical boundaries
prior to chemotherapy. 19 In order for INRT to be delivered
safely and in an optimal manner, staging imaging
procedures should be of the highest possible accuracy,
and the fusion of pre- and post-chemotherapy scanning
images should be as precise as possible. Stringent
procedures must be established, and all staging images
should be acquired with the patient in the same
position as that which will be the treatment position.
Pre-chemotherapy imaging data should always include
contrast-enhanced computed tomography and FDG-PET
scans, as these PET scans allow the identiﬁcation of
additional involved nodes in a relatively large number
of patients. 12,22,23
Due to possible difﬁculties in the superimposition
of initially involved lymph nodes onto the post-
chemotherapy computed tomography simulation, a
prospective quality assurance program should therefore
be organized for centers implementing this technique.
In France a program has already been implemented in
which patient imaging data are exchanged via a secured
and encrypted internet connection. All French centers
are interconnected and can exchange data allowing
radiation ﬁelds to be prospectively veriﬁed in real time.
Further optimization of the INRT concept concerns the
reduction of the irradiated volume by using sophisticated
radiation delivery techniques 24−26 which allow more
conformal therapy and increased sparing of surrounding
normal tissues. The INRT concept and its implemen-
tation need to be adapted for worldwide use. This
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will hopefully be achieved by reaching a consensus in
the recently founded International Lymphoma Radiation
Oncology Group (ILROG).
In conclusion, the INRT concept is simple and
a strongly individualized treatment. It is based on
modern imaging and radiation techniques which allow
increased sparing of normal tissue. Its implementation
requires further improvement in order to achieve greater
homogeneity among international groups.
2.3. Identiﬁcation and prevention of late toxicity after
curative treatment for malignant lymphoma
The successful treatment of patients with HL and
aggressive NHL has resulted in an awareness of long-
term therapy-related toxicity in the surviving patients,
and the LG was one of the ﬁrst to address this
topic. The memorable meeting held in Paris in 1989,
honoring Prof. Tubiana as one of the most important
founders of the Group, resulted in a database collected
from all over the world consisting of over 14,000
well-documented patients with HL. 27 The survival data
from this large cohort were compared with healthy
populations matched by sex, age, and country and
showed for the ﬁrst time that HL patients experienced
an ongoing excessive death rate years after the end of
treatment. The observed to expected ratio of death not
related to the disease increased with time from 1.79 in
the 0−4 year period after treatment to 3.08 after 15 years
and beyond. Major causes of late death were related
to secondary malignancies, cardiovascular events, and
infections with cumulative risk exceeding that of death
from HL 15 years and beyond after treatment. 3,4,27
For many years, the LG has collected data related to
late toxicity in HL patients. Here, not only potential
lethal toxicity was studied, but also causes of late
morbidity. Extensive data on hormonal abnormalities
(thyroid, gonadal), pulmonary function, cardiac function,
and also quality-of-life were analyzed. 10,11,28
Studying HL patients for late therapy-related morbidity
and mortality is relatively easy given the young age
and high survival rates. In such patients the incidence
and prevalence of confounding co-morbidity is far less
than in patients with aggressive NHL. As a consequence,
analysis of late toxicity had only rarely been performed
in small numbers of NHL patients. The LG succeeded
in retrospectively analyzing a cohort of 757 NHL
patients who were treated in the 1980’s and 1990’s,
and they focused on late morbidity and mortality. This
study required effort to collect appropriate morbidity
and mortality data with the help of national cancer
registries and the Nijmegen cardiovascular morbidity
registry. Using competing risk models, it appeared
that − after careful correction for the already high
prevalence of cardiovascular diseases and malignancies
in a population over the age of 50 − the excess of
additional cardiovascular events was very high. The
standardized incidence ratio of chronic heart failure was
markedly increased (SIR=5.4, 95%CI 4.1−6.9) with an
absolute excess risk of 208 cases per 10,000 person-
years, whereas the incidence of coronary artery disease
matched the general population. 7,8 Because half of the
patients died of aggressive NHL prior to living long
enough to experience a second cancer, the risk of
secondary malignancies was limited to patients treated
before the age of 45 years and with an SIR of 3.6 (95%CI
2.0−6.0) and 16.7 (95%CI 1.4−93) for solid tumors and
leukemia, respectively. 9 Data on other toxicities showed
that infertility (15-year cumulative incidence rate 29%),
renal insufﬁciency (11%), acquired hypertension (8%), and
disabling neuropathy (13%) were also frequent. Salvage
treatment improved the risk in most cases. 7
An important ongoing study focuses on the re-
habilitation and quality of long-term survival in all
6658 HL patients treated in EORTC trials beginning
with the H1 trial. In a tremendous effort, all 3603
surviving patients whose address could be found have
been sent an extensive lifestyle questionnaire together
with questionnaires related to co-morbidity and chronic
fatigue, since more than 60% of survivors complain
of persistent fatigue. 28 Over 2000 questionnaires have
been returned and are being analyzed. So far, the
impact of treatment regimens on premature ovarian
failure (POF) occurrence and motherhood has been
studied. Non-alkylating chemotherapy appeared to carry
little to no excess risk of POF. Linear dose–response
relationships could be established for POF with both
alkylating chemotherapy and age at treatment. 29 We
also investigated the impact of HL on parenthood by
comparing survivors with matched general population
controls (UNECE Generations and Gender Survey) avail-
able for France and The Netherlands. HL survivors had
slightly but signiﬁcantly fewer children after treatment
than general population controls. The difference only
concerned patients who had children before treatment.
However, in patients who attempted post-treatment
parenthood, three-quarters succeeded. 30 Simultaneous
with this effort, case record forms are being sent to all
participating centers to collect detailed clinical follow-
up data focusing on treatment-related toxicity. Finally,
in-depth studies focusing on pharmacogenetics and
psychology will be launched to address the very serious
problem of chronic fatigue in HL survivors.
In conclusion, early on investigators were aware of
treatment-related side effects, and major attention has
been given to following-up on these survivors. Careful
prospective collection of detailed data is the basis of clin-
ical epidemiology studies with the objective of assessing
the long-term risk of treatment-related complications,
rehabilitation and quality-of-life of survivors, and to
adapt the treatment strategy to disease aggressiveness.
ejc supplements 10, no. 1 (2012) 105–111 109
2.4. Advanced stages
The use of IFRT after chemotherapy for advanced HL is
controversial. The LG conducted a trial (H34) in which
patients with previously untreated stage III or IV HL
in complete remission (CR) after 6−8 cycles of MOPP-
ABV were randomly assigned to receive either no further
treatment or IFRT. Patients in partial remission (PR)
were given IFRT. The results demonstrated that in
patients with CR after MOPP-ABV chemotherapy IFRT
did not signiﬁcantly improve the outcome (8-year
overall survival rate 82%) and that outcome was not
inﬂuenced by violation of the radiotherapy protocol. 31,32
Radiotherapy, however, may provide beneﬁt to patients
with a PR after chemotherapy (8-year overall survival
rate 84%). 33 Subsequently, an intergroup phase III trial
(EORTC 20012, 550 patients) comparing BEACOPP versus
ABVD in high-risk HL patients has recently been closed,
and ﬁnal analysis is expected later this year.
2.5. Relapsed Hodgkin Lymphoma
High-dose chemotherapy (HDCT) followed by autologous
stem-cell transplantation (PBSCT) has become the
standard treatment for patients with relapsed HL. In
these patients, the intensity of treatment has been
studied in an intergroup trial.The trial demonstrated that
compared to standard BEAM chemotherapy alone, HDCT
was associated with more adverse effects and did not
improve the prognosis. 34
2.6. Non-Hodgkin Lymphoma (NHL)
Although the LG has gained experience in the treatment
of NHL, the annual patient accrual has been too
limited to conduct trials within an acceptable time.
Consequently, a decision was made in 2004 to focus
on HL, and so the results of NHL studies will not be
discussed further in this paper. Recent trials that have
been conducted, in part in cooperation with other groups,
have concerned: primary CNS-NHL patients treated by
MBVP and radiotherapy 35; newly diagnosed patients with
stage III and IV low-grade NHL treated by ﬂudarabine
compared to CVP 36; relapsed/resistant follicular NHL pa-
tients given rituximab maintenance to improve clinical
results in patients with or without rituximab during
induction 37; the progressive and cautious treatment
emphasizing geriatric assessment in diffuse large B-cell
and peripheral T-cell NHL in the frail elderly 38; the
prognostic impact of speciﬁc treatment protocols on the
tumor microenvironment in follicular lymphoma 39; and
the comparison of gemcitabine–(R)CHOP versus (R)CHOP
in untreated aggressive NHL. In this study, gemcitabine
did not improve the results. 40
3. Conclusion
Hodgkin Lymphoma is a text book example of success
in anti-neoplastic treatment thanks to the strategy that
has been followed over the last 50 years. The LG has
played a major role in this story together with the GELA
since the early 1990s and more recently with the FIL.
Twenty years ago, the LG took the leadership in this ﬁeld
of clinical research and served as a good example for
other European cooperative groups such as the GHSG
and the British National Lymphoma Investigation. With
the development of more complex studies, i.e., studies
including topics in clinical, biological, and social sciences,
the LG will continue to participate in trials exploring
new treatment strategies and taking into consideration
that decision making in cancer treatment should involve
patients as much as possible for the beneﬁt of all
parties.
4. Future strategy of the group
Current studies concern the long-term outcome and
involve HL survivors of the 1964–2004 trials. Another
recently approved study is the retrospective analysis
of updated data pooled from studies completed by the
LG and other cooperative groups worldwide. Upcoming
studies are planned for patients with relapsed HL and in
elderly HL patients. Translational research (TR) studies
will focus on PET imaging and biomarkers. The LG has
accumulated expertise in integrating imaging into the
treatment sequence and is building on this expertise
in the upcoming H11 study on advanced-stage HL. The
imaging platform will be used to look for early signs
of activity of new targeted drugs. Collaborations with
national groups for studies in relapsing HL patients will
be continued. Biomarker studies will be done based on
old material, and TR projects and biobanking efforts
will be expanded to include parafﬁn-embedded, frozen
material and blood (from H10 and H11 studies) to check
for markers of late toxicity (e.g. cardiotoxicity). The GELA
and the LG are developing the H12 trial, the successor to
the H10 study in limited-stage HL together with the FIL.
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